{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:22:33Z","timestamp":1790796153248,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hodgkin lymphoma (HL) Reed Sternberg cells express tumor-associated antigens (TAA) that are potential targets for cellular therapies. We recently demonstrated that TAA-specific T cells (TAA-Ts) targeting WT1, PRAME, and Survivin were safe and associated with prolonged time to progression in solid tumors. Hence, we evaluated whether TAA-Ts when given alone or with nivolumab were safe and could elicit antitumor effects in vivo in patients with relapsed\/refractory (r\/r) HL. Ten patients were infused with TAA-Ts (8 autologous and 2 allogeneic) for active HL (n = 8) or as adjuvant therapy after hematopoietic stem cell transplant (n = 2). Six patients received nivolumab priming before TAA-Ts and continued until disease progression or unacceptable toxicity. All 10 products recognized 1 or more TAAs and were polyfunctional. Patients were monitored for safety for 6 weeks after the TAA-Ts and for response until disease progression. The infusions were safe with no clear dose-limiting toxicities. Patients receiving TAA-Ts as adjuvant therapy remain in continued remission at 3+ years. Of the 8 patients with active disease, 1 patient had a complete response and 7 had stable disease at 3 months, 3 of whom remain with stable disease at 1 year. Antigen spreading and long-term persistence of TAA-Ts in vivo were observed in responding patients. Nivolumab priming impacted TAA-T recognition and persistence. In conclusion, treatment of patients with r\/r HL with TAA-Ts alone or in combination with nivolumab was safe and produced promising results. This trial was registered at www.clinicaltrials.gov as #NCT022039303 and #NCT03843294.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005343","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T15:05:52Z","timestamp":1631113552000},"page":"473-485","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Tumor-associated antigen\u2013specific T cells with nivolumab are safe and persist in vivo in relapsed\/refractory Hodgkin lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5530-0201","authenticated-orcid":false,"given":"Hema","family":"Dave","sequence":"first","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"},{"name":"Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Terpilowski","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Mai","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-7314","authenticated-orcid":false,"given":"Keri","family":"Toner","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"},{"name":"Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5421-5889","authenticated-orcid":false,"given":"Melanie","family":"Grant","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Stanojevic","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lazarski","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Shibli","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Bien","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Maglo","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahmida","family":"Hoq","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"},{"name":"Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-2168","authenticated-orcid":false,"given":"Reuven","family":"Schore","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"},{"name":"Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Glenn","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute\/University of Utah, Salt Lake City, UT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute\/University of Utah, Salt Lake City, UT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hanley","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"},{"name":"Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-3073","authenticated-orcid":false,"given":"Richard","family":"Ambinder","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Hospital, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, Washington, DC;"},{"name":"Department of Pediatrics, George Washington School of Medicine and Health Sciences, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"issue":"8","key":"2022011816244268800_B1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol."},{"issue":"11","key":"2022011816244268800_B2","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022011816244268800_B3","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood."},{"issue":"10","key":"2022011816244268800_B4","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after Anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther."},{"issue":"10","key":"2022011816244268800_B5","first-page":"664","article-title":"Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia","volume":"16","author":"Maude","year":"2018","journal-title":"Clin Adv Hematol Oncol."},{"issue":"9","key":"2022011816244268800_B6","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest."},{"issue":"32","key":"2022011816244268800_B7","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022011816244268800_B8","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2022011816244268800_B9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12885-019-5415-9","article-title":"Challenges of driving CD30-directed CAR-T cells to the clinic","volume":"19","author":"Grover","year":"2019","journal-title":"BMC Cancer."},{"issue":"4","key":"2022011816244268800_B10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med."},{"issue":"14","key":"2022011816244268800_B11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022011816244268800_B12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood."},{"issue":"14","key":"2022011816244268800_B13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood."},{"issue":"9","key":"2022011816244268800_B14","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"issue":"26","key":"2022011816244268800_B15","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.19.00177","article-title":"Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study","volume":"37","author":"Hont","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022011816244268800_B16","first-page":"5","article-title":"Staging and response assessment in lymphomas: the new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Linchuang Zhongliuxue Zazhi."},{"issue":"12","key":"2022011816244268800_B17","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/mt.2011.167","article-title":"Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma","volume":"19","author":"Gerdemann","year":"2011","journal-title":"Mol Ther."},{"issue":"3","key":"2022011816244268800_B18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcyt.2019.02.004","article-title":"Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells","volume":"21","author":"Tanna","year":"2019","journal-title":"Cytotherapy."},{"issue":"18","key":"2022011816244268800_B19","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-13-0955","article-title":"Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia: implications for immunotherapy","volume":"19","author":"Weber","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"285","key":"2022011816244268800_B20","doi-asserted-by":"crossref","first-page":"285ra63","DOI":"10.1126\/scitranslmed.aaa2546","article-title":"CMV-specific T cells generated from na\u00efve T cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Hanley","year":"2015","journal-title":"Sci Transl Med."},{"issue":"19","key":"2022011816244268800_B21","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","article-title":"Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells","volume":"114","author":"Robins","year":"2009","journal-title":"Blood."},{"issue":"1","key":"2022011816244268800_B22","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1038\/ncomms3680","article-title":"Using synthetic templates to design an unbiased multiplex PCR assay","volume":"4","author":"Carlson","year":"2013","journal-title":"Nat Commun."},{"issue":"1-2","key":"2022011816244268800_B23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jim.2011.09.001","article-title":"Ultra-sensitive detection of rare T cell clones","volume":"375","author":"Robins","year":"2012","journal-title":"J Immunol Methods."},{"issue":"13","key":"2022011816244268800_B24","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.20.02224","article-title":"T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects","volume":"39","author":"Vasileiou","year":"2021","journal-title":"J Clin Oncol."},{"issue":"19","key":"2022011816244268800_B25","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS post-allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood."},{"issue":"554","key":"2022011816244268800_B26","doi-asserted-by":"crossref","first-page":"eaaz3339","DOI":"10.1126\/scitranslmed.aaz3339","article-title":"The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma","volume":"12","author":"Lulla","year":"2020","journal-title":"Sci Transl Med."},{"issue":"254","key":"2022011816244268800_B27","doi-asserted-by":"crossref","first-page":"254ra128","DOI":"10.1126\/scitranslmed.3008918","article-title":"Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response","volume":"6","author":"Kvistborg","year":"2014","journal-title":"Sci Transl Med."},{"issue":"9","key":"2022011816244268800_B28","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"40","key":"2022011816244268800_B29","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1073\/pnas.1110814108","article-title":"Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab","volume":"108","author":"Yuan","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2022011816244268800_B30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"2022011816244268800_B31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fimmu.2014.00069","article-title":"The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment","volume":"5","author":"De Sanctis","year":"2014","journal-title":"Front Immunol."},{"issue":"19","key":"2022011816244268800_B32","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood."},{"issue":"23","key":"2022011816244268800_B33","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022011816244268800_B34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","article-title":"Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT","volume":"5","author":"Kanate","year":"2019","journal-title":"JAMA Oncol."},{"issue":"25","key":"2022011816244268800_B35","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood."},{"issue":"14","key":"2022011816244268800_B36","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022011816244268800_B37","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun."},{"key":"2022011816244268800_B38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fimmu.2018.00385","article-title":"Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells","volume":"9","author":"Lichtenegger","year":"2018","journal-title":"Front Immunol."},{"issue":"5","key":"2022011816244268800_B39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","article-title":"Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor","volume":"31","author":"Foster","year":"2008","journal-title":"J Immunother."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2023011854","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/2\/473\/1860450\/advancesadv2021005343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/2\/473\/1860450\/advancesadv2021005343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T20:47:24Z","timestamp":1642538844000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/2\/473\/476808\/Tumor-associated-antigen-specific-T-cells-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005343","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2023011854","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}